Evoke Pharma (NASDAQ: EVOK) reported Q2 EPS of ($0.93), versus ($6.71) reported last year. Revenue for the quarter came in at $2.55 million, versus $1.13 million reported last year.

• Based on net sales generated in the first two quarters of 2024, Evoke is revising its 2024 guidance to a range of $11- 12 million from $14 million, still reflecting over a 100% increase from the previous year if achieved. Evoke’s 2024 guidance is dependent on its current business and expectations, including recent growth rates in net sales, assumptions regarding reimbursements and prescription fills, as well as factors that are outside of our control, such as the global macroeconomic and geopolitical environment, continued supply chain constraints and inflationary pressures.

For earnings history and earnings-related data on Evoke Pharma (EVOK) click here.